Zaloguj się

Gotowe bibliografie tematyczne / RANK ligand inhibitor / Artykuły w czasopismach

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: RANK ligand inhibitor.

Artykuły w czasopismach na temat „RANK ligand inhibitor”

Autor: Grafiati

Data publikacji: 2 czerwca 2025

Data aktualizacji: 31 lipca 2025

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „RANK ligand inhibitor”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

Ikhena, Deborah E., Shimeng Liu, Stacy Kujawa, et al. "RANKL/RANK Pathway and Its Inhibitor RANK-Fc in Uterine Leiomyoma Growth." Journal of Clinical Endocrinology & Metabolism 103, no. 5 (2018): 1842–49. http://dx.doi.org/10.1210/jc.2017-01585.

Pełny tekst źródła

Streszczenie:

Abstract Context Uterine leiomyomas are the most common type of gynecologic tumor in women. Objective To determine the role of the cytokine receptor activator of nuclear factor κ-Β ligand (RANKL); its receptor, receptor activator of nuclear factor κ-Β (RANK); and the RANKL/RANK pathway inhibitor RANK-Fc in leiomyoma growth. Design Messenger RNA (mRNA) or protein levels of RANKL, RANK, and proliferation markers cyclin D1 and Ki67 were assessed in various leiomyoma tissues and cell populations. Human xenograft experiments were performed to determine the effects of RANK-Fc on leiomyoma growth in

Style APA, Harvard, Vancouver, ISO itp.

2

Sutton, Emily E., and Daniel M. Riche. "Denosumab, a RANK Ligand Inhibitor, for Postmenopausal Women with Osteoporosis." Annals of Pharmacotherapy 46, no. 7-8 (2012): 1000–1009. http://dx.doi.org/10.1345/aph.1q543.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Passaponti, Sofia, Leonardo Ermini, Giulia Acconci, et al. "Rank-Rankl-Opg Axis in Multiple Sclerosis: The Contribution of Placenta." Cells 11, no. 8 (2022): 1357. http://dx.doi.org/10.3390/cells11081357.

Pełny tekst źródła

Streszczenie:

Women with multiple sclerosis (MS) can safely become pregnant and give birth, with no side effects or impediments. Pregnancy is generally accepted as a period of well-being in which relapses have a softer evolution, particularly in the third trimester. Herein, we hypothesized that the placenta, via its “secretome”, could contribute to the recognized beneficial effects of pregnancy on MS activity. We focused on a well-known receptor/ligand/decoy receptor system, such as the one composed by the receptor activator of nuclear factor-kB (RANK), its ligand (RANKL), and the decoy receptor osteoproteg

Style APA, Harvard, Vancouver, ISO itp.

4

Liu, Huan, Ning-Yu Ru, Yue Cai та ін. "The OPG/RANKL/RANK system modulates calcification of common carotid artery in simulated microgravity rats by regulating NF-κB pathway". Canadian Journal of Physiology and Pharmacology 100, № 4 (2022): 324–33. http://dx.doi.org/10.1139/cjpp-2021-0329.

Pełny tekst źródła

Streszczenie:

Functional and structural adaptation of common carotid artery could be one of the important causes of postflight orthostatic intolerance after microgravity exposure, the mechanisms of which remain unclear. Recent evidence indicates that long-term spaceflight increases carotid artery stiffness, which might present a high risk to astronaut health and postflight working ability. Studies have suggested that vascular calcification is a common pathological change in cardiovascular diseases that is mainly manifested as an increase in vascular stiffness. Therefore, this study investigated whether simu

Style APA, Harvard, Vancouver, ISO itp.

5

Kiss, Emese, Zénó Kuluncsics, Zoltán Kiss, and Gyula Poór. "Biotechnological advances in monoclonal antibody therapy: the RANK ligand inhibitor antibody." Orvosi Hetilap 151, no. 52 (2010): 2137–44. http://dx.doi.org/10.1556/oh.2010.29010.

Pełny tekst źródła

Streszczenie:

Biológiai gyógyszereket a múlt század közepe óta használ az orvostudomány. Napjainkban szemtanúi lehetünk intenzív fejlődésüknek és elterjedésüknek a klinikai gyakorlatban. Eddig 350 millió beteg részesült a forgalomban lévő körülbelül 250 biológiai terápia valamelyikében. Biológiai készítmények közé sorolandóak a fehérjetermészetű makromolekulák, amelyeknek tömeges gyártását a biotechnológia tette lehetővé. E gyártási modell fogalmát, amely során élő szervezeteket használnak fel a termelésben, magyar mérnök, Ereky Károly vezette be. A szerzők jelen összefoglalóban elsősorban a biotechnológiai

Style APA, Harvard, Vancouver, ISO itp.

6

Kerboua, Esma. "Place of rank ligand inhibitor in giant cell tumour of bone." Journal of Clinical Oncology 42, no. 16_suppl (2024): e23511-e23511. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e23511.

Pełny tekst źródła

Streszczenie:

e23511 Background: Giant cell tumour of bone (GCTB) is a locally aggressive and osteolytic tumour.The peak incidence is during the third and fourth decades of life. The majority of tumours occur in the metaepiphyseal (end) region of the long bones. Surgical resection is the preferred treatment option, if possible but it is a tumor which always poses progressive problems. Denosumab is indicated in recurrent or unresectable GCTB. Methods: We report a series of 70 patients treated for GCT at the medical oncology department of the CPMC (Algiers) in collaboration with the orthopedics department of

Style APA, Harvard, Vancouver, ISO itp.

7

Li, Xiaodong, Michael S. Ominsky, Marina Stolina, et al. "Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin." Bone 45, no. 4 (2009): 669–76. http://dx.doi.org/10.1016/j.bone.2009.06.011.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

Tsourdi, Elena, Tilman D. Rachner, Martina Rauner, Christine Hamann, and Lorenz C. Hofbauer. "Denosumab for bone diseases: translating bone biology into targeted therapy." European Journal of Endocrinology 165, no. 6 (2011): 833–40. http://dx.doi.org/10.1530/eje-11-0454.

Pełny tekst źródła

Streszczenie:

Signalling of receptor activator of nuclear factor-κB (RANK) ligand (RANKL) through RANK is a critical pathway to regulate the differentiation and activity of osteoclasts and, hence, a master regulator of bone resorption. Increased RANKL activity has been demonstrated in diseases characterised by excessive bone loss such as osteoporosis, rheumatoid arthritis and osteolytic bone metastases. The development and approval of denosumab, a fully MAB against RANKL, has heralded a new era in the treatment of bone diseases by providing a potent, targeted and reversible inhibitor of bone resorption. Thi

Style APA, Harvard, Vancouver, ISO itp.

9

Fessler, Beate. "Knochenmetastasen beim fortgeschrittenen Mammakarzinom: Risiko Skelett-bezogener Ereignisse senken." Onkologische Welt 03, no. 01 (2012): 34. http://dx.doi.org/10.1055/s-0038-1631070.

Pełny tekst źródła

Streszczenie:

Knochenmetastasen sind eine häufige Komplikation bei Frauen mit fortgeschrittenem Mammakarzinom. Mit dem RANK-Ligand-Inhibitor Denosumab (XGEVA®) lässt sich die Dauer bis zum Auftreten des ersten Skelett-bezogenen Ereignisses (SRE) im Vergleich zur Standardtherapie verzögern.

Style APA, Harvard, Vancouver, ISO itp.

10

Kwon, H. S., J. Y. Kim, S. U. Kim, et al. "AB0055 THE ROLES OF OX40L AND TNF BISPECIFIC ANTIBODY IN OSTEOCLASTOGENESIS." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1206.2–1207. http://dx.doi.org/10.1136/annrheumdis-2023-eular.5450.

Pełny tekst źródła

Streszczenie:

BackgroundRheumatoid arthritis (RA) is a chronic, inflammatory disease that leads to progressive cartilage and bone destruction. OX40 ligand (OX40L) is expressed predominantly on antigen-presenting cells and highly associated with joint inflammation in RA[1]. Yet, the role of OX40L in osteoclastogenesis is unclear.ObjectivesIn this study, we investigated the effects of dual blocking of TNF and OX40L by bispecific antibody (IMB-101) on RANKL-induced osteoclastogenesis.MethodsCD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMCs) of healthy donors (n=6). CD14+ monocytes we

Style APA, Harvard, Vancouver, ISO itp.

11

Frick, Kevin K., Kelly LaPlante та David A. Bushinsky. "RANK ligand and TNF-α mediate acid-induced bone calcium efflux in vitro". American Journal of Physiology-Renal Physiology 289, № 5 (2005): F1005—F1011. http://dx.doi.org/10.1152/ajprenal.00420.2004.

Pełny tekst źródła

Streszczenie:

Chronic metabolic acidosis stimulates net calcium efflux from bone due to increased osteoclastic bone resorption and decreased osteoblastic collagen synthesis. Previously, we determined that incubation of neonatal mouse calvariae in medium simulating physiological metabolic acidosis leads to a significant, cyclooxygenase-dependent, increase in RNA for bone cell receptor activator of NF-κB ligand (RANKL) compared with incubation in neutral pH medium. In this study, we tested the hypothesis that the acid-mediated increase in RANKL expression is a primary mechanism for the stimulated osteoclastic

Style APA, Harvard, Vancouver, ISO itp.

12

V.A., Patil, and Desai M.H. "Biology of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) and Osteoprotegerin (OPG) in Periodontal Health and Disease - A Review." PJSR 7, no. 1 (2014): 58–63. https://doi.org/10.5281/zenodo.8260189.

Pełny tekst źródła

Streszczenie:

Periodontitis is a destructive disease that targets tooth-supporting structures through complex and multifactorial pathogenic processes. Alveolar bone destruction, a hallmark of periodontitis progression and one of the major causes of tooth loss in human, is mediated by the host immune and inflammatory response to microbial challenge. The discovery of the receptor activator of nuclear factor-kappa B (RANK)/ RANK ligand (RANKL)/osteoprotegerin (OPG) axis has improved the knowledge of bone metabolism regulation. The RANKL/RANK interaction is needed for differentiation and maturation of osteoclas

Style APA, Harvard, Vancouver, ISO itp.

13

Strickling, Jarred, and Michael J. Wilkowski. "Severe, Symptomatic Hypocalcemia due to Denosumab Administration: Treatment and Clinical Course." Case Reports in Nephrology and Dialysis 9, no. 1 (2019): 33–41. http://dx.doi.org/10.1159/000499824.

Pełny tekst źródła

Streszczenie:

Denosumab is a receptor activator of nuclear factor kappa-B (RANK) ligand inhibitor used in the treatment of osteoporosis. Blockade of RANK ligand prevents osteoclastic resorption of bone, but in doing so impairs the parathyroid hormone (PTH)-driven maintenance of serum calcium. A subsequent elevation of PTH remains active at sites other than bone, potentially lowering serum phosphate by inhibiting proximal tubular reabsorption. We present 2 patients who developed severe, symptomatic hypocalcemia after administration of denosumab. These patients provide an opportunity to describe the clinical

Style APA, Harvard, Vancouver, ISO itp.

14

Dempster, David W., Cheryl L. Lambing, Paul J. Kostenuik, and Andreas Grauer. "Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data." Clinical Therapeutics 34, no. 3 (2012): 521–36. http://dx.doi.org/10.1016/j.clinthera.2012.02.002.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

15

Nosaka, Kisato, Takeshi Miyamoto, Tatsunori Sakai, Hiroaki Mitsuya, Toshio Suda та Masao Matsuoka. "Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor κB ligand on adult T-cell leukemia cells". Blood 99, № 2 (2002): 634–40. http://dx.doi.org/10.1182/blood.v99.2.634.

Pełny tekst źródła

Streszczenie:

Abstract Hypercalcemia is one of the most frequent and serious complications in patients with adult T-cell leukemia (ATL) and is due to marked bone resorption by accumulation of osteoclasts (OCLs). Although several cytokines such as interleukin 1 and parathyroid hormone–related protein are thought to be involved in the development of high serum Ca++ levels, its precise underlying mechanism remains unknown. This study analyzed the expression of various genes that are thought to regulate serum Ca++ levels in ATL and showed that the overexpression of the receptor activator of nuclear factor κB (R

Style APA, Harvard, Vancouver, ISO itp.

16

Yan, Bo, Yan Li, Shaoju Min, et al. "Effects of the Bone/Bone Marrow Microenvironments on Prostate Cancer Cells and CD59 Expression." BioMed Research International 2020 (April 6, 2020): 1–13. http://dx.doi.org/10.1155/2020/2753414.

Pełny tekst źródła

Streszczenie:

Objective. To evaluate the effects of human bone marrow mesenchymal stem cells (hBMSCs) and osteoblasts (hFOB1.19) on PC3 prostate cancer cells. Methods. To simulate the in vivo interaction between the bone/bone marrow microenvironments and prostate cancer cells, we established cocultures of PC3 cells with hBMSC or hFOB1.19 cells and evaluated their effects on the proliferation, cell cycle distribution, cell migration, and invasion of PC3 cells. Quantitative reverse transcription polymerase chain reaction was used to detect CD59 mRNA expression in PC3 cells. The expression of receptor activato

Style APA, Harvard, Vancouver, ISO itp.

17

Li, Jiali, Christina Yau, Michael Campbell, Laura Esserman, John W. Park, and Hope S. Rugo. "Correlation of receptor activator of nuclear factor kappa b (RANK) expression in breast cancer (BC) at the time of diagnosis with recurrence-free survival (RFS) and risk of bone-dominant metastases (BDM) in the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657)." Journal of Clinical Oncology 30, no. 27_suppl (2012): 2. http://dx.doi.org/10.1200/jco.2012.30.27_suppl.2.

Pełny tekst źródła

Streszczenie:

2 Background: RANK is a tumor necrosis factor receptor family protein that is critical to bone turnover. The ligand to RANK (RANKL) can induce metastases from RANK-expressing tumor cells, and treatment with a RANKL inhibitor can reduce BC metastases (mets) in pre-clinical models and there is an FDA approved drug that targets RANKL. Osteoprotegerin (OPG) is a RANKL decoy receptor that blocks the interaction of RANK/RANKL. I-SPY 1 was a multicenter neoadjuvant trial with well annotated gene expression data and detailed clinical outcomes; we studied the impact of RANK expression on both RFS and B

Style APA, Harvard, Vancouver, ISO itp.

18

Czupkallo, Lukasz, Mansur Rahnama, Dominik Kielbowicz, Michal Lobacz, and Maryla Kozicka-Czupkallo. "Bone metabolism and RANKL/RANK/OPG trail in periodontal disease." Current Issues in Pharmacy and Medical Sciences 29, no. 4 (2016): 171–75. http://dx.doi.org/10.1515/cipms-2016-0036.

Pełny tekst źródła

Streszczenie:

Abstract Periodontal disease is an inflammatory disease of multifactorial etiology. In order for it to appear there must come to an imbalance between the effects of pathogens and host defense mechanisms. As a result of its course the destruction of structures supporting the teeth appears (periodontium, cement, bone), and consequently leads to teeth loosening and loss. In recent years, the participation of RANKL/RANK/OPG in bone remodeling process was highligted. At the molecular level the bone resorption is regulated through the interaction of the ligand receptor activator of nuclear NF-kappa

Style APA, Harvard, Vancouver, ISO itp.

19

Tomaszewska, Ewa, Halyna Rudyk, Siemowit Muszyński, et al. "Prenatal Fumonisin Exposure Impairs Bone Development via Disturbances in the OC/Leptin and RANKL/RANK/OPG Systems in Weaned Rat Offspring." International Journal of Molecular Sciences 24, no. 10 (2023): 8743. http://dx.doi.org/10.3390/ijms24108743.

Pełny tekst źródła

Streszczenie:

The goal of the current study was to examine the effects of prenatal exposure to fumonisins (FBs) on bone properties and metabolism in weaned rat offspring divided into groups intoxicated with FBs at either 0 (the 0 FB group), 60 (the 60 FB group), or 90 mg/kg b.w. 0 (the 90 FB group). Female and male offspring exposed to FBs at a dose of 60 mg/kg b.w. had heavier femora. Mechanical bone parameters changed in a sex and FBs dose-dependent manner. Growth hormone and osteoprotegerin decreased in both sexes, regardless of FBs dose. In males osteocalcin decreased, while receptor activator for nucle

Style APA, Harvard, Vancouver, ISO itp.

20

Kumar, Meera, and Robert G. Lowery. "A High-Throughput Method for Measuring Drug Residence Time Using the Transcreener ADP Assay." SLAS DISCOVERY: Advancing the Science of Drug Discovery 22, no. 7 (2017): 915–22. http://dx.doi.org/10.1177/2472555217695080.

Pełny tekst źródła

Streszczenie:

Analysis of drug–target residence times during drug development can result in improved efficacy, increased therapeutic window, and reduced side effects. Residence time can be estimated as the reciprocal of the dissociation rate ( koff) of an inhibitor from its target. The traditional methods for measuring koff require synthesis of labeled ligands or low-throughput label-free methods. To provide an alternative that is better suited to an automated high-throughput screening (HTS) environment, we adapted a classic “jump dilution” catalytic assay method for determination of koff values for kinase

Style APA, Harvard, Vancouver, ISO itp.

21

Chakraborty, Sandeep. "DOCLASP - Docking ligands to target proteins using spatial and electrostatic congruence extracted from a known holoenzyme and applying simple geometrical transformations." F1000Research 3 (June 16, 2016): 262. http://dx.doi.org/10.12688/f1000research.5145.3.

Pełny tekst źródła

Streszczenie:

The ability to accurately and effectively predict the interaction between proteins and small drug-like compounds has long intrigued researchers for pedagogic, humanitarian and economic reasons. Protein docking methods (AutoDock, GOLD, DOCK, FlexX and Glide to name a few) rank a large number of possible conformations of protein-ligand complexes using fast algorithms. Previously, it has been shown that structural congruence leading to the same enzymatic function necessitates the congruence of electrostatic properties (CLASP). The current work presents a methodology for docking a ligand into a ta

Style APA, Harvard, Vancouver, ISO itp.

22

Anjan Bera, Shatarupa Dutta, Aparajita Sadhya, et al. "Management of giant cell tumor of bone in the era of denosumab: A case series and review of the literature." Asian Journal of Medical Sciences 14, no. 1 (2023): 238–42. http://dx.doi.org/10.3126/ajms.v14i1.48969.

Pełny tekst źródła

Streszczenie:

Giant cell tumor (GCT) of the bone also known as osteoclastoma typically arises from the meta-epiphyseal region of the long bone and comprises 5% of all bone tumors and 20% of benign bone tumors. Understanding pathogenesis is the key to successful systemic therapy with denosumab, a RANK-ligand inhibitor. In this context, we report seven GCT bone-treated denosumab and radiotherapy cases with a diverse clinical presentation from our institute, NRS Medical College, and Hospital Kolkata.

Style APA, Harvard, Vancouver, ISO itp.

23

Iuliani, Michele, Sonia Simonetti, Leonardo Cristofani, et al. "Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC)." Journal for ImmunoTherapy of Cancer 12, no. 6 (2024): e009432. http://dx.doi.org/10.1136/jitc-2024-009432.

Pełny tekst źródła

Streszczenie:

BackgroundReceptor activator of nuclear factor kappa-B ligand (RANKL) can directly promote tumor growth and indirectly support tumor immune evasion by altering the tumor microenvironment and immune cell responses. This study aimed to assess the prognostic significance of soluble RANKL in patients with advanced non-small cell lung cancer (NSCLC) receiving programmed cell death 1 (PD1)/programmed death-ligand 1 (PDL1) checkpoint inhibitor therapy.MethodsPlasma RANKL levels were measured in 100 patients with advanced NSCLC without bone metastases undergoing monotherapy with PD1/PDL1 checkpoint in

Style APA, Harvard, Vancouver, ISO itp.

24

Go, Eun Mi, Ju Hee Oh, Jin Hee Park, Soo Young Lee, and Na Kyung Lee. "Spi-C positively regulates RANKL-mediated osteoclast differentiation and function." Experimental & Molecular Medicine 52, no. 4 (2020): 691–701. http://dx.doi.org/10.1038/s12276-020-0427-8.

Pełny tekst źródła

Streszczenie:

Abstract Spi-C is an SPI-group erythroblast transformation-specific domain transcription factor expressed during B-cell development. Here, we report that Spi-C is a novel receptor activator of nuclear factor-κB ligand (RANKL)-inducible protein that positively regulates RANKL-mediated osteoclast differentiation and function. Knockdown of Spi-C decreased the expression of RANKL-induced nuclear factor of activated T-cells, cytoplasmic 1, receptor activator of nuclear factor-κB (RANK), and tartrate-resistant acid phosphatase (TRAP), resulting in a marked decrease in the number of TRAP-positive mul

Style APA, Harvard, Vancouver, ISO itp.

25

Huang, Min Mei, Cindy Leo, Suwen Wei, E. Richard Stanley, Stephen Doberstein, and Haishan Lin. "IL-34, in Synergy with RANK Ligand, Promotes Osteoclast Development through the CSF-1 Receptor." Blood 112, no. 11 (2008): 5392. http://dx.doi.org/10.1182/blood.v112.11.5392.5392.

Pełny tekst źródła

Streszczenie:

Abstract IL-34 is a newly identified cytokine that binds to the CSF-1 receptor (CSF-1R), promotes monocyte viability, and stimulates macrophage colony formation (Lin et al., 2008). Here we demonstrate that human IL-34 induced tyrosine phosphorylation of the CSF-1R in cells of a mouse MacCsf1r−/−.huCSF-1R macrophage line. MacCsf1r−/−.huCSF-1R cells were obtained by retroviral transduction of the human CSF-1R into cells of the MacCsf1r−/− macrophage line (Yu et al., 2008) derived from bone marrow macrophages isolated from a CSF-1R-deficient mouse. In addition, IL-34 stimulated the downstream sig

Style APA, Harvard, Vancouver, ISO itp.

26

Cheung, Angela M. "Osteoporosis: Connection to urologic health." Canadian Urological Association Journal 8, no. 7-8 (2014): 156. http://dx.doi.org/10.5489/cuaj.2313.

Pełny tekst źródła

Streszczenie:

Men with prostate cancer are often treated with androgen deprivation therapy (ADT), which is associated with reduced bone mineral density (BMD) and a higher risk for fractures. Maintenance of optimum bone health throughout the natural course of prostate cancer is an important aspect in the management of this patient population. Bone targeted therapies such as bisphosphonates and the RANK ligand inhibitor denosumab have been demonstrated to reduce skeletal-related events in patients with metastatic cancer, while denosumab has also been shown to reduce the risk of fracture in men undergoing ADT

Style APA, Harvard, Vancouver, ISO itp.

27

Somayaji, Shankari N., Samantha Ritchie, Mahnaz Sahraei, Ian Marriott та Michael C. Hudson. "Staphylococcus aureus Induces Expression of Receptor Activator of NF-κB Ligand and Prostaglandin E2 in Infected Murine Osteoblasts". Infection and Immunity 76, № 11 (2008): 5120–26. http://dx.doi.org/10.1128/iai.00228-08.

Pełny tekst źródła

Streszczenie:

ABSTRACT Osteomyelitis is an inflammatory disease of the bone that is characterized by the presence of necrotic bone tissue and increased osteoclast activity. Staphylococcus aureus is responsible for approximately 80% of all cases of human osteomyelitis. While the disease is especially difficult to treat, the pathogenesis of S. aureus-induced osteomyelitis is poorly understood. Elucidating the molecular mechanisms by which S. aureus induces osteomyelitis could lead to a better understanding of the disease and its progression and development of new treatments. Osteoblasts can produce several so

Style APA, Harvard, Vancouver, ISO itp.

28

Tian, Yaru, Shuangqing Lu, Yulan Sun, et al. "Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: A propensity score-matched study." Journal of Clinical Oncology 42, no. 23_suppl (2024): 206. http://dx.doi.org/10.1200/jco.2024.42.23_suppl.206.

Pełny tekst źródła

Streszczenie:

206 Background: Addition of programmed cell death ligand 1 (PD-L1) inhibitors or programmed cell death 1 (PD-1) inhibitors to etoposide‐platinum (EP) chemotherapy has become the standard first-line regimen for ES-SCLC. The clinical efficacy and safety between the two types of immune checkpoint inhibitors (ICIs) remain controversial. We conduct the retrospective study and propensity score-matched analysis to explore the potential differences between them. Methods: Patients diagnosed with ES-SCLC and treated by EP plus PD-L1 or PD-1 inhibitors at Shandong Cancer Hospital between March 2019 and N

Style APA, Harvard, Vancouver, ISO itp.

29

Tian, Yaru, Shuangqing Lu, Yulan Sun, et al. "Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: A propensity score-matched study." Journal of Clinical Oncology 42, no. 16_suppl (2024): 8086. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.8086.

Pełny tekst źródła

Streszczenie:

8086 Background: Addition of programmed cell death ligand 1 (PD-L1) inhibitors or programmed cell death 1 (PD-1) inhibitors to etoposide‐platinum (EP) chemotherapy has become the standard first-line regimen for ES-SCLC. The clinical efficacy and safety between the two types of immune checkpoint inhibitors (ICIs) remain controversial. We conduct the retrospective study and propensity score-matched analysis to explore the potential differences between them. Methods: Patients diagnosed with ES-SCLC and treated by EP plus PD-L1 or PD-1 inhibitors at Shandong Cancer Hospital between March 2019 and

Style APA, Harvard, Vancouver, ISO itp.

30

Li, Hao, Huafei Liu, Ning Zhang, and Zemin Zhu. "Involvement of the G-Protein-Coupled Receptor 4 in the Increased Expression of RANK/RANKL/OPG System and Neurotrophins by Nucleus Pulposus Cells under the Degenerated Intervertebral Disc-Like Acidic Microenvironment." BioMed Research International 2020 (May 30, 2020): 1–12. http://dx.doi.org/10.1155/2020/1328436.

Pełny tekst źródła

Streszczenie:

Intervertebral disc (IVD) degeneration is associated with local inflammation and increased expression of neurotrophins. Acidic microenvironment is believed to cause the progression of IVD degeneration. However, there is a paucity of information regarding the relationship between acidic microenvironment and the inflammation and expression of neurotrophins in IVD. G-protein-coupled receptor 4 (GPR4) is a pH-sensing receptor, which can activate the inflammation and increase the expression levels of nerve growth factor in acidic microenvironment. In this study, culture media with pH 7.2 (represent

Style APA, Harvard, Vancouver, ISO itp.

31

Gregorczyk, Izabela, Agnieszka Jasiecka-Mikołajczyk та Tomasz Maślanka. "Blockade of NF-κB Translocation and of RANKL/RANK Interaction Decreases the Frequency of Th2 and Th17 Cells Capable of IL-4 and IL-17 Production, Respectively, in a Mouse Model of Allergic Asthma". Molecules 26, № 11 (2021): 3117. http://dx.doi.org/10.3390/molecules26113117.

Pełny tekst źródła

Streszczenie:

The main purpose of this study was to investigate whether the blockade of the interaction between the receptor activator of nuclear factor-κB (NF-ĸB) ligand (RANKL) and its receptor RANK as well as the blockade of NF-κB inhibitor kinase (IKK) and of NF-κB translocation have the potential to suppress the pathogenesis of allergic asthma by inhibition and/or enhancement of the production by CD4+ and CD8+ T cells of important cytokines promoting (i.e., IL-4 and IL-17) and/or inhibiting (i.e., IL-10 and TGF-β), respectively, the development of allergic asthma. Studies using ovalbumin(OVA)-immunized

Style APA, Harvard, Vancouver, ISO itp.

32

Oner, Gizem, Glenn Broeckx, Christophe Van Berckelaer, et al. "Abstract PD9-03: Breast Cancer Microenvironment Change After Neoadjuvant Endocrine Treatment Breast Cancer Microenvironment Change After Neoadjuvant Endocrine Treatment." Cancer Research 83, no. 5_Supplement (2023): PD9–03—PD9–03. http://dx.doi.org/10.1158/1538-7445.sabcs22-pd9-03.

Pełny tekst źródła

Streszczenie:

Abstract Background: Estrogen receptor positive (ER+)/HER-2 negative breast cancer (BC) is considered to be an immunologically cold tumor compared to triple negative breast cancer. Therefore, the tumor microenvironment (TME) of ER+/HER-2 negative BC is understudied. The receptor activator of nuclear factor-kB ligand (RANKL)-RANK pathway was first identified, as mediator of T and dendritic cells interaction, but it is mostly known for its role as key regulator of bone remodeling and pathophysiology of bone metastases. RANK is a member of the tumor necrosis factor receptor (TNFR) superfamily tha

Style APA, Harvard, Vancouver, ISO itp.

33

Kaczoruk-Wieremczuk, Magdalena, Paulina Adamska, Łukasz Jan Adamski, Piotr Wychowański, Barbara Alicja Jereczek-Fossa, and Anna Starzyńska. "Oral Surgery Procedures in a Patient with Hajdu-Cheney Syndrome Treated with Denosumab—A Rare Case Report." International Journal of Environmental Research and Public Health 18, no. 17 (2021): 9099. http://dx.doi.org/10.3390/ijerph18179099.

Pełny tekst źródła

Streszczenie:

Background: Hajdu-Cheney syndrome (HCS) is a very rare autosomal-dominant congenital disease associated with mutations in the NOTCH2 gene. This disorder affects the connective tissue and is characterized by severe bone resorption. Hajdu-Cheney syndrome most frequently affects the head and feet bones (acroosteolysis). Case report: We present an extremely rare case of a 34-year-old male with Hajdu-Cheney syndrome. The patient was admitted to the Department of Oral Surgery, Medical University of Gdańsk, in order to perform the extraction of three teeth. These teeth were not eligible for conservat

Style APA, Harvard, Vancouver, ISO itp.

34

Otto, Sven, Sebastian Baumann, Michael Ehrenfeld, and Christoph Pautke. "Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection." Journal of Cranio-Maxillofacial Surgery 41, no. 7 (2013): 694–98. http://dx.doi.org/10.1016/j.jcms.2013.05.038.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

35

Crockett, Julie C., Norbert Schütze, Denise Tosh та ін. "The Matricellular Protein CYR61 Inhibits Osteoclastogenesis by a Mechanism Independent of αvβ3 and αvβ5". Endocrinology 148, № 12 (2007): 5761–68. http://dx.doi.org/10.1210/en.2007-0473.

Pełny tekst źródła

Streszczenie:

Cysteine-rich protein 61 (CYR61/CCN1) belongs to the family of CCN matricellular proteins. Most of the known effects of CCN proteins appear to be due to binding to extracellular growth factors or integrins, including αvβ3 and αvβ5. Although CYR61 can stimulate osteoblast differentiation, until now the effect of CYR61 on osteoclasts was unknown. We demonstrate that recombinant human CYR61 inhibits the formation of multinucleated, αvβ3-positive, or tartrate-resistant acid phosphatase-positive human, mouse, and rabbit osteoclasts in vitro. CYR61 markedly reduced the expression of the osteoclast p

Style APA, Harvard, Vancouver, ISO itp.

36

Hung, Yi-Ting, Wen-Tien Wu, Ru-Ping Lee, Ting-Kuo Yao, and Kuang-Ting Yeh. "Beyond Bone Remodeling: Denosumab’s Multisystemic Benefits in Musculoskeletal Health, Metabolism, and Age-Related Diseases—A Narrative Review." Biomedicines 13, no. 3 (2025): 732. https://doi.org/10.3390/biomedicines13030732.

Pełny tekst źródła

Streszczenie:

Background: Denosumab, a receptor activator of nuclear factor kappa-Β ligand (RANKL) inhibitor, demonstrates therapeutic effects beyond traditional osteoporosis management through the RANK/RANKL/osteoprotegerin pathway. Methods: This narrative review analyzed 37 studies (2018–2024) examining denosumab’s broader physiological effects and clinical applications. Results: Long-term safety data spanning 10 years showed sustained fracture prevention efficacy with a favorable benefit/risk profile. Compared to bisphosphonates, denosumab demonstrated superior outcomes in bone mineral density improvemen

Style APA, Harvard, Vancouver, ISO itp.

37

Teramachi, Jumpei, Masahiro Hiasa, Asuka Oda, et al. "Pim Inhibition Suppresses Osteoclastogenesis and Tumor Growth in Myeloma." Blood 126, no. 23 (2015): 4203. http://dx.doi.org/10.1182/blood.v126.23.4203.4203.

Pełny tekst źródła

Streszczenie:

Abstract Devastating bone destruction in multiple myeloma (MM) still remains a significant clinical problem. In pursuing factors responsible for MM tumor expansion and bone destruction, we found that the serine/threonine kinase Pim-2 is constitutively over-expressed as an anti-apoptotic mediator, and further up-regulated in MM cells when cocultured with bone marrow stromal cells or osteoclasts (OCs) (Leukemia, 2011). We also demonstrated that Pim inhibition is able to induce bone formation while suppressing MM tumor growth (Leukemia, 2015). However, the impact of Pim inhibition on MM-induced b

Style APA, Harvard, Vancouver, ISO itp.

38

Kushlinskii, N. E., E. S. Gershtein, Yu N. Solov’ev та ін. "Receptor Activator of Nuclear Transcription Factor NF-κB (RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone Tumors". Bulletin of Experimental Biology and Medicine 163, № 4 (2017): 478–81. http://dx.doi.org/10.1007/s10517-017-3832-9.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

39

Cui, Pengfei, Di Huang, Zhaozhen Wu, et al. "Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer." Therapeutic Advances in Medical Oncology 12 (January 2020): 175883592092203. http://dx.doi.org/10.1177/1758835920922033.

Pełny tekst źródła

Streszczenie:

Background: Cutaneous adverse events (AEs) have been positively associated with immune checkpoint inhibitor (ICI) efficacy in patients with melanoma, but little is known regarding the association between checkpoint inhibitor pneumonitis (CIP) and programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) inhibitor efficacy in non-small cell lung cancer (NSCLC). Methods: A single-institution, retrospective medical record review of patients with advanced or recurrent NSCLC who were treated with PD-1/PD-L1 inhibitors between 1 September 2015 and 1 June 2019 was conducted. A total of 2

Style APA, Harvard, Vancouver, ISO itp.

40

Fukumoto, Seiji, and Toshio Matsumoto. "Recent advances in the management of osteoporosis." F1000Research 6 (May 5, 2017): 625. http://dx.doi.org/10.12688/f1000research.10682.1.

Pełny tekst źródła

Streszczenie:

There has been substantial progress in the management of patients with osteoporosis and the prevention of osteoporotic fractures. Currently available strong anti-resorptive agents are bisphosphonates and an anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody, denosumab. Although bisphosphonates and denosumab both inhibit bone resorption and prevent vertebral and non-vertebral fractures, their mechanisms of action are different. Whereas bisphosphonates’ effects on bone mineral density and fracture peak around 3 to 5 years and become plateaued, those of denosumab are mainta

Style APA, Harvard, Vancouver, ISO itp.

41

Ahn, Sun-Hee, Zhihao Chen, Jinkyung Lee, et al. "Inhibitory Effects of 2N1HIA (2-(3-(2-Fluoro-4-Methoxyphenyl)-6-Oxo-1(6H)-Pyridazinyl)-N-1H-Indol-5-Ylacetamide) on Osteoclast Differentiation via Suppressing Cathepsin K Expression." Molecules 23, no. 12 (2018): 3139. http://dx.doi.org/10.3390/molecules23123139.

Pełny tekst źródła

Streszczenie:

Osteoclasts are large multinucleated cells which are induced by the regulation of the receptor activator of nuclear factor kappa-Β ligand (RANKL), which is important in bone resorption. Excessive osteoclast differentiation can cause pathologic bone loss and destruction. Numerous studies have targeted molecules inhibiting RANKL signaling or bone resorption activity. In this study, 11 compounds from commercial libraries were examined for their effect on RANKL-induced osteoclast differentiation. Of these compounds, only 2-(3-(2-fluoro-4-methoxyphenyl)-6-oxo-1(6H)-pyridazinyl)-N-1H-indol-5-ylaceta

Style APA, Harvard, Vancouver, ISO itp.

42

Villa, I., E. Mrak, A. Rubinacci, F. Ravasi, and F. Guidobono. "CGRP inhibits osteoprotegerin production in human osteoblast-like cells via cAMP/PKA-dependent pathway." American Journal of Physiology-Cell Physiology 291, no. 3 (2006): C529—C537. http://dx.doi.org/10.1152/ajpcell.00354.2005.

Pełny tekst źródła

Streszczenie:

The osteoprotegerin (OPG)/receptor activator of nuclear factor-κB ligand (RANKL)/receptor activator of nuclear factor-κB (RANK) system was evaluated as a potential target of CGRP anabolic activity on bone. Primary cultures of human osteoblast-like cells (hOB) express calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1, and, because CGRP stimulates cAMP (one of the modulators of OPG production in osteoblasts), it was investigated whether it affects OPG secretion and expression in hOB. CGRP treatment of hOB (10−11 M–10−7 M) dose-dependently inhibited OPG secretion w

Style APA, Harvard, Vancouver, ISO itp.

43

Mazreku, Merita, L’uboš Danišovič, Martin Klein, and Mária Kleinová. "Recent Stem-Cell-Based and Stem-Cell-Free Possibilities for the Therapeutic Management of the Osteonecrosis of the Jaw." Biomolecules 15, no. 4 (2025): 595. https://doi.org/10.3390/biom15040595.

Pełny tekst źródła

Streszczenie:

Osteonecrosis of the jaw (ONJ), including the maxilla and mandible, is considered a challenging therapeutic problem, mainly due to the lack of understanding of its pathogenesis. It is well known that ONJ is a severe side effect caused by certain medications used to treat bone metastasis and osteoporosis, such as bisphosphonates, which inhibit bone resorption. Other therapeutics with similar side effects are, for instance, receptor activators of nuclear factor kappa-B ligand (RANK-L) inhibitor (denosumab), tyrosine kinase inhibitors (sunitinib), and antiangiogenics (bevacizumab). The conservati

Style APA, Harvard, Vancouver, ISO itp.

44

Ansalone, Cecilia, John Cole, Sabarinadh Chilaka, et al. "TNF is a homoeostatic regulator of distinct epigenetically primed human osteoclast precursors." Annals of the Rheumatic Diseases 80, no. 6 (2021): 748–57. http://dx.doi.org/10.1136/annrheumdis-2020-219262.

Pełny tekst źródła

Streszczenie:

Objectives Circulating myeloid precursors are responsible for post-natal osteoclast (OC) differentiation and skeletal health, although the exact human precursors have not been defined. Enhanced osteoclastogenesis contributes to joint destruction in rheumatoid arthritis (RA) and tumour necrosis factor (TNF) is a well-known pro-osteoclastogenic factor. Herein, we investigated the interplay between receptor activator of nuclear factor kappa-Β ligand (RANK-L), indispensable for fusion of myeloid precursors and the normal development of OCs, and TNF in directing the differentiation of diverse pre-O

Style APA, Harvard, Vancouver, ISO itp.

45

Haaber, Jacob, Lene M. Knudsen, Inger M. Dahl, Niels Abildgaard, Marianne Lodahl, and Thomas Rasmussen. "Myeloma Cell Expression of Candidate Genes for Osteolytic Bone Disease - Over-Expression of DKK1 Correlates with Clinical Bone Involvment." Blood 108, no. 11 (2006): 3406. http://dx.doi.org/10.1182/blood.v108.11.3406.3406.

Pełny tekst źródła

Streszczenie:

Abstract The etiology of the osteolytic bone disease (OBD) in multiple myeloma (MM) is not fully understood but seems to involve interactions between myeloma cells and the bone marrow microenvironment. Over-expression of the osteoclast activation cytokine, receptor activator of nuclear factor-κB ligand (RANKL), and decreased expression of the inhibitor of RANKL, called osteoprotegerin (OPG), is believed to be important. Macrophage inflammatory proteins are also reported to play a role in osteoclast activation. Recently, the role of osteoblast inactivation in OBD has come into focus, especially

Style APA, Harvard, Vancouver, ISO itp.

46

Mons, Elma, Robbert Q. Kim, and Monique P. C. Mulder. "Technologies for Direct Detection of Covalent Protein—Drug Adducts." Pharmaceuticals 16, no. 4 (2023): 547. http://dx.doi.org/10.3390/ph16040547.

Pełny tekst źródła

Streszczenie:

In the past two decades, drug candidates with a covalent binding mode have gained the interest of medicinal chemists, as several covalent anticancer drugs have successfully reached the clinic. As a covalent binding mode changes the relevant parameters to rank inhibitor potency and investigate structure-activity relationship (SAR), it is important to gather experimental evidence on the existence of a covalent protein–drug adduct. In this work, we review established methods and technologies for the direct detection of a covalent protein–drug adduct, illustrated with examples from (recent) drug d

Style APA, Harvard, Vancouver, ISO itp.

47

Cassoni, Andrea, Umberto Romeo, Valentina Terenzi, et al. "Adalimumab: Another Medication Related to Osteonecrosis of the Jaws?" Case Reports in Dentistry 2016 (2016): 1–6. http://dx.doi.org/10.1155/2016/2856926.

Pełny tekst źródła

Streszczenie:

Objective.The acronym MRONJ has been created in order to identify “Medication-Related Osteonecrosis of the Jaw,” observed after the use of Bisphosphonates, RANK ligand inhibitor, and antiangiogenic medications. Only a case of osteonecrosis of the jaw in a Chron’s disease patient following a course of Bisphosphonate and Adalimumab therapy has been recently described, so that it has been supposed that also this medication could promote manifestation of osteonecrosis.Clinical Case. On August, 2014, a 63-year-old female with a history of idiopathic arthritis treated with medical treatment with Ada

Style APA, Harvard, Vancouver, ISO itp.

48

Cao, Yenong, Muhammad Zubair Afzal, and Keisuke Shirai. "Does denosumab offer survival benefits? Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors." Journal of Clinical Oncology 39, no. 15_suppl (2021): e21039-e21039. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e21039.

Pełny tekst źródła

Streszczenie:

e21039 Background: Lung cancer is the leading cause of cancer-related death in the United States. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small-cell lung cancer (NSCLC). Denosumab is a humanized monoclonal antibody to RANK ligand used to prevent skeletal-related events of bone metastases in solid tumors. In preclinical and some clinical studies, denosumab have shown to have some anti-tumor properties. We are reporting the clinical outcomes in our NSCLC patients who received RANKL inhibitor in combination with ICIs. Methods: This observational study used ret

Style APA, Harvard, Vancouver, ISO itp.

49

Taveira, Gabriela Monte Tenorio, Felipe Da Silva Marinho, Antonio Marcelo Gonçalves de Souza, and Wagner cabral Gomes Carneiro. "Locally advanced GCTB recurrence after neoadjuvant denosumab use." Journal of Clinical Oncology 38, no. 15_suppl (2020): e23507-e23507. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e23507.

Pełny tekst źródła

Streszczenie:

e23507 Background: Giant Cell Tumor of Bone is a RANK/RANK-ligand (RANKL) positive, aggressive, locally destructive tumor leading to pain and impairment of movement and limb function. Even though surgery remains the standard treatment, the use of denosumab, monoclonal antibody RANK-L inhibitor is associated with tumor response and surgical morbidity, with downstaging benefit. Methods: All GCTB patients from 2005 to 2020 from Pernambuco Cancer Center Hospital were included in the study and followed up. All patients received Denosumab 120mg on D1, D8 and D15 (attack phase), and maintenance phase

Style APA, Harvard, Vancouver, ISO itp.

50

Saylor, Philip J., Richard J. Lee, and Matthew R. Smith. "Emerging Therapies to Prevent Skeletal Morbidity in Men With Prostate Cancer." Journal of Clinical Oncology 29, no. 27 (2011): 3705–14. http://dx.doi.org/10.1200/jco.2010.34.4994.

Pełny tekst źródła

Streszczenie:

Skeletal morbidity is a prominent burden to men with advanced prostate cancer throughout the natural history of the disease. Bone metastases can cause pain and greatly elevate the risk for fractures and other structural complications. Distinct from the problem of metastases, treatment-related osteoporosis and associated fragility fractures are potential complications of androgen-deprivation therapy. Bone-targeted therapies for prostate cancer have therefore been the focus of considerable research and drug development efforts. The osteoclast is a validated therapeutic target in the management o

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!